JP6764021B2 - ナイセリア・メニンギティディスのワクチン - Google Patents

ナイセリア・メニンギティディスのワクチン Download PDF

Info

Publication number
JP6764021B2
JP6764021B2 JP2019511860A JP2019511860A JP6764021B2 JP 6764021 B2 JP6764021 B2 JP 6764021B2 JP 2019511860 A JP2019511860 A JP 2019511860A JP 2019511860 A JP2019511860 A JP 2019511860A JP 6764021 B2 JP6764021 B2 JP 6764021B2
Authority
JP
Japan
Prior art keywords
polysaccharide
vaccine
conjugate
carrier protein
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019511860A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019526573A (ja
JP2019526573A5 (cg-RX-API-DMAC7.html
Inventor
リチャード・デイヴィッド・ケンシンガ−
スティーヴン・エル・ハウザー
Original Assignee
サノフィ パスツール インコーポレイテッド
サノフィ パスツール インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サノフィ パスツール インコーポレイテッド, サノフィ パスツール インコーポレイテッド filed Critical サノフィ パスツール インコーポレイテッド
Publication of JP2019526573A publication Critical patent/JP2019526573A/ja
Publication of JP2019526573A5 publication Critical patent/JP2019526573A5/ja
Application granted granted Critical
Publication of JP6764021B2 publication Critical patent/JP6764021B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2019511860A 2016-09-02 2017-09-01 ナイセリア・メニンギティディスのワクチン Active JP6764021B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662383279P 2016-09-02 2016-09-02
US62/383,279 2016-09-02
US201762468695P 2017-03-08 2017-03-08
US62/468,695 2017-03-08
US201762505525P 2017-05-12 2017-05-12
US62/505,525 2017-05-12
PCT/US2017/049856 WO2018045286A1 (en) 2016-09-02 2017-09-01 Neisseria meningitidis vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020150938A Division JP7028932B2 (ja) 2016-09-02 2020-09-09 ナイセリア・メニンギティディスのワクチン

Publications (3)

Publication Number Publication Date
JP2019526573A JP2019526573A (ja) 2019-09-19
JP2019526573A5 JP2019526573A5 (cg-RX-API-DMAC7.html) 2020-05-14
JP6764021B2 true JP6764021B2 (ja) 2020-09-30

Family

ID=59846741

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019511860A Active JP6764021B2 (ja) 2016-09-02 2017-09-01 ナイセリア・メニンギティディスのワクチン
JP2020150938A Active JP7028932B2 (ja) 2016-09-02 2020-09-09 ナイセリア・メニンギティディスのワクチン
JP2022021720A Active JP7329087B2 (ja) 2016-09-02 2022-02-16 ナイセリア・メニンギティディスのワクチン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020150938A Active JP7028932B2 (ja) 2016-09-02 2020-09-09 ナイセリア・メニンギティディスのワクチン
JP2022021720A Active JP7329087B2 (ja) 2016-09-02 2022-02-16 ナイセリア・メニンギティディスのワクチン

Country Status (24)

Country Link
US (4) US11147866B2 (cg-RX-API-DMAC7.html)
EP (2) EP4309670A3 (cg-RX-API-DMAC7.html)
JP (3) JP6764021B2 (cg-RX-API-DMAC7.html)
KR (1) KR102692762B1 (cg-RX-API-DMAC7.html)
CN (2) CN109890413B (cg-RX-API-DMAC7.html)
AU (2) AU2017321863B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019003992A2 (cg-RX-API-DMAC7.html)
CA (1) CA3033364A1 (cg-RX-API-DMAC7.html)
DK (1) DK3506935T3 (cg-RX-API-DMAC7.html)
ES (1) ES2974992T3 (cg-RX-API-DMAC7.html)
FI (1) FI3506935T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240433T1 (cg-RX-API-DMAC7.html)
HU (1) HUE066007T2 (cg-RX-API-DMAC7.html)
LT (1) LT3506935T (cg-RX-API-DMAC7.html)
MX (1) MX2019002489A (cg-RX-API-DMAC7.html)
PH (1) PH12019500399B1 (cg-RX-API-DMAC7.html)
PL (1) PL3506935T3 (cg-RX-API-DMAC7.html)
PT (1) PT3506935T (cg-RX-API-DMAC7.html)
RS (1) RS65362B1 (cg-RX-API-DMAC7.html)
SA (1) SA519401227B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201901394XA (cg-RX-API-DMAC7.html)
SI (1) SI3506935T1 (cg-RX-API-DMAC7.html)
WO (1) WO2018045286A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201901402B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2283857T3 (da) * 2005-06-27 2019-10-28 Glaxosmithkline Biologicals Sa Vaccinesammensætning omfattende konjugerede native N. Meningitidis kapselpolysaccharider
WO2018045286A1 (en) 2016-09-02 2018-03-08 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
EP3632465A1 (en) 2018-10-03 2020-04-08 Sanofi Pasteur Inc. Combined immunization against meningococcal disease and human papillomavirus
WO2021099982A1 (en) 2019-11-22 2021-05-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
TW202245836A (zh) 2021-02-19 2022-12-01 美商賽諾菲巴斯德公司 重組ｂ型腦膜炎球菌疫苗
JP2025512330A (ja) 2022-04-11 2025-04-17 サノフィ パスツール インコーポレイテッド シアノ水素化ホウ素ナトリウムとのタンパク質－糖コンジュゲーション
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物
JP2024075506A (ja) * 2022-11-22 2024-06-03 ファイザー・インク コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US5097020A (en) 1983-07-05 1992-03-17 The University Of Rochester Immunogenic conjugates
US4882317A (en) 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US5371197A (en) 1991-09-24 1994-12-06 Merck & Co., Inc. Protein-dimeric polysaccharide conjugate vaccine
FR2682388B1 (fr) 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
ES2171418T3 (es) * 1992-08-31 2002-09-16 Baxter Healthcare Sa Vacunas contra neisseria meningitidis del grupo c.
US5425946A (en) 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
NZ304715A (en) 1995-03-22 1999-07-29 Jackson H M Found Military Med Production of immunogenic constructs using organic cyanylating reagents to activate carbohydrates and then coupling the carbohydrate to a protein, peptide or hapten
US20030157129A1 (en) 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
US6309646B1 (en) 1996-05-09 2001-10-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates
US5965714A (en) 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6645503B1 (en) 1998-03-10 2003-11-11 Wyeth Holdings Corporation Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria
CA2264970A1 (en) 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
WO2000010599A2 (en) 1998-08-19 2000-03-02 North American Vaccine, Inc. IMMUNOGENIC β-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE
US6585973B1 (en) 1998-10-29 2003-07-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method for preparing solid phase conjugated vaccine
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
FR2791895B1 (fr) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
WO2000071725A2 (en) 1999-05-19 2000-11-30 Chiron S.P.A. Combination neisserial compositions
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
DE10012370A1 (de) 2000-03-14 2001-09-27 Chiron Behring Gmbh & Co Adjuvans für Vakzinen
WO2002000249A2 (en) 2000-06-29 2002-01-03 Glaxosmithkline Biologicals S.A. Multivalent vaccine composition
US6673905B2 (en) 2000-08-09 2004-01-06 The United States Of America As Represented By The Department Of Health And Human Services Conjugation of biomolecules using Diels-Alder cycloaddition
EP2332581B1 (en) * 2001-01-23 2015-07-01 Sanofi Pasteur Inc. Tri- or tetravalent meningococcal polysaccharide-CRM197 conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
CN100350972C (zh) 2001-07-26 2007-11-28 启龙股份公司 含有铝佐剂和组氨酸的疫苗
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CU23031A1 (es) 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
WO2003080678A1 (en) 2002-03-26 2003-10-02 Chiron Srl Modified saccharides having improved stability in water
AU2002309259A1 (en) 2002-05-09 2003-11-11 Massimo Porro Improved polysaccharide and glycoconjugate vaccines_____________
AU2003299501A1 (en) 2002-05-16 2004-05-04 Aventis Pasteur, Inc. Animal component free meningococcal polysaccharide fermentation and seedbank development
AU2003257003A1 (en) 2002-07-30 2004-02-16 Baxter Healthcare S.A. Chimeric multivalent polysaccharide conjugate vaccines
GB0220198D0 (en) 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
ATE352316T1 (de) 2002-11-01 2007-02-15 Glaxosmithkline Biolog Sa Immunogene zusammensetzung
CN102302776B (zh) 2003-01-30 2014-06-18 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
WO2004103400A2 (en) 2003-05-07 2004-12-02 Aventis Pasteur,Inc. Multivalent meningococcal derivatized polysaccharide-protein conjugates and corresponding vaccines
US6933137B2 (en) 2003-05-16 2005-08-23 Aventis Pasteur Animal component free meningococcal polysaccharide fermentation and seedbank development
EP2851088A1 (en) 2003-06-23 2015-03-25 Baxter International Inc. Vaccines against group Y Neisseria meningitidis and meningoccal combinations thereof
ATE414535T1 (de) 2003-06-23 2008-12-15 Baxter Int Trägerproteine für impfstoffe
US8048432B2 (en) 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
AU2004263135B2 (en) 2003-08-06 2010-11-25 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
KR101113726B1 (ko) 2003-08-12 2012-02-27 리폭센 테크놀로지즈 리미티드 단백질 유도 및 컨쥬게이션용 시알산 유도체
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
CN103405761A (zh) 2003-10-02 2013-11-27 诺华疫苗和诊断有限公司 多种脑膜炎球菌血清群的液体疫苗
CU23236A1 (es) 2003-12-03 2007-09-26 Ct Ingenieria Genetica Biotech PROTEINA NMB0928 Y SU USO EN FORMULACIONES FARMACéUTICAS P
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
NZ550533A (en) 2004-04-30 2010-02-26 Novartis Vaccines & Diagnostic Meningococcal conjugate vaccination comprising N. meningitidis and diphtheria toxin
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
US7875708B2 (en) 2004-08-12 2011-01-25 Lipoxen Technologies Limited Sialic acid derivatives
EP2351582A1 (en) 2004-08-30 2011-08-03 Sanofi Pasteur, Inc. Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
MX2007003292A (es) 2004-09-21 2007-09-07 Sanofi Pasteur Inc Conjugados y vacuna con proteinas de polisacarido derivadas meningococales multivalentes.
WO2006042542A2 (en) 2004-10-19 2006-04-27 Statens Serum Institut Production of tetanus, diphtheria, and pertussis toxins and toxoids using fermentation media containing no components of animal or soy origin
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
ES2533248T3 (es) 2005-05-06 2015-04-08 Novartis Ag Inmunógenos para vacunas contra Meningitidis A
GB0513071D0 (en) * 2005-06-27 2005-08-03 Glaxosmithkline Biolog Sa Immunogenic composition
DK2283857T3 (da) * 2005-06-27 2019-10-28 Glaxosmithkline Biologicals Sa Vaccinesammensætning omfattende konjugerede native N. Meningitidis kapselpolysaccharider
GB0513069D0 (en) * 2005-06-27 2005-08-03 Glaxosmithkline Biolog Sa Immunogenic composition
AU2012203419B2 (en) * 2005-06-27 2014-06-26 Glaxosmithkline Biologicals S.A. Immunogenic composition
CA2621023C (en) 2005-09-01 2019-07-02 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Multiple vaccination including serogroup c meningococcus
US8679770B2 (en) 2005-09-05 2014-03-25 Glaxo Smith Kline Biologicals S.A. Serum bactericidal assay for N. meningitidis specific antisera
JP2009521434A (ja) 2005-12-22 2009-06-04 サノフィ パストゥール インコーポレイテッド 髄膜炎菌由来の誘導体化多糖類−タンパク質の多価コンジュゲートおよびワクチン
ES2707499T3 (es) 2005-12-22 2019-04-03 Glaxosmithkline Biologicals Sa Vacuna de conjugado de polisacárido neumocócico
EP1976857A4 (en) 2006-01-13 2011-08-03 Baxter Int PROCESS FOR CLEANING POLYSACCHARIDES
EP1993604B1 (en) 2006-03-17 2015-12-02 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Methods for preparing complex multivalent immunogenic conjugates
US20080026002A1 (en) 2006-03-22 2008-01-31 Lisa Danzig Regimens for immunisation with meningococcal conjugates
CU23572A1 (es) 2006-03-31 2010-09-30 Ct Ingenieria Genetica Biotech Composición farmacéutica que comprende la proteína nmb0938
CU23575A1 (es) 2006-03-31 2010-09-30 Ct Ingenieria Genetica Biotech Composición farmacéutica que comprende la proteína nmb0606
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
JP5275983B2 (ja) 2006-06-12 2013-08-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
US7491517B2 (en) 2006-07-19 2009-02-17 Jeeri R Reddy Method of producing meningococcal meningitis vaccine for Neisseria meningitidis serotypes A,C,Y, and W-135
DK2056871T3 (en) 2006-08-07 2018-02-26 Harvard College PROTEIN MATRIX VACCINES AND PROCEDURES FOR THE PREPARATION AND ADMINISTRATION OF SUCH VACCINES
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
US8398985B2 (en) 2007-04-23 2013-03-19 Serum Institute Of India Ltd. Antigenic polysaccharides and process for their preparation
ES2555786T3 (es) 2007-06-04 2016-01-08 Glaxosmithkline Biologicals Sa Formulación de vacunas contra la meningitis
ES2621359T3 (es) 2007-06-20 2017-07-03 Pfizer Ireland Pharmaceuticals Polisacáridos modificados para vacunas conjugadas
JP5702600B2 (ja) 2007-07-03 2015-04-15 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド オリゴシアル酸誘導体、製造方法および免疫学的使用
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
ATE553774T1 (de) 2007-10-19 2012-05-15 Novartis Ag Meningokokkenimpfstoffformulierungen
MX2010008799A (es) 2008-03-05 2010-09-07 Sanofi Pasteur Proceso para estabilizar una composicion de vacuna que contiene adyuvante.
GB0810894D0 (en) 2008-06-13 2008-07-23 Novartis Vaccines & Diagnostic Conjugated saccharide
DK2315747T3 (en) 2008-07-21 2018-02-26 Brigham & Womens Hospital Inc Methods and Compositions of Synthetic Beta-1.6 Glucosamine Oligosaccharides
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
JP5841044B2 (ja) 2009-03-23 2016-01-06 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 複合糖質ワクチン
NZ622048A (en) 2009-08-27 2015-10-30 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
AU2010310985B2 (en) 2009-10-27 2014-11-06 Glaxosmithkline Biologicals S.A. Modified meningococcal fHBP polypeptides
WO2011080595A2 (en) 2009-12-30 2011-07-07 Novartis Ag Polysaccharide immunogens conjugated to e. coli carrier proteins
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
US10478483B2 (en) * 2010-06-25 2019-11-19 Glaxosmithkline Biologicals Sa Combinations of meningococcal factor H binding proteins
US9120848B2 (en) 2010-09-23 2015-09-01 Harvey Kaplan Non-aqueous synthesis of polysaccharide-protein conjugates for vaccines
KR20140026392A (ko) * 2011-03-02 2014-03-05 노파르티스 아게 저용량의 항원 및/또는 보조제를 갖는 조합 백신
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
DK2709656T3 (da) 2011-05-18 2019-06-24 Matrivax Inc Proteinmatrix-vaccinesammensætninger omfattende polykationer
TR201909110T4 (tr) 2011-09-14 2019-07-22 Glaxosmithkline Biologicals Sa Sakarit-protein glikokonjugatları yapmaya yönelik yöntemler.
CA2854934A1 (en) 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
IN2012MU00206A (cg-RX-API-DMAC7.html) * 2012-01-20 2013-08-09
WO2013114268A1 (en) * 2012-01-30 2013-08-08 Serum Institute Of India Ltd. Immunogenic composition
MX351993B (es) 2012-03-09 2017-11-03 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
BR112014029313A2 (pt) 2012-05-22 2017-06-27 Novartis Ag conjugado de meningococos do sorogrupo x
CN104428008B (zh) 2012-05-24 2020-10-09 美国政府(由卫生和人类服务部的部长所代表) 多价脑膜炎球菌缀合物及制备缀合物的方法
MX2014014649A (es) 2012-05-30 2015-08-06 Brigham & Womens Hospital Composiciones de polisacáridos y métodos de uso.
CN104487086B (zh) 2012-07-07 2019-08-30 巴拉特生物技术国际有限公司 无动物源的不含酒精的疫苗组合物及其制备方法
HUE049531T2 (hu) 2012-08-16 2020-10-28 Pfizer Glikokonjugációs eljárások és kompozíciók
CN102809656B (zh) 2012-08-26 2014-09-03 云南沃森生物技术股份有限公司 一种脑膜炎球菌多糖结合疫苗成品各群游离多糖含量的测定方法
AU2013311702A1 (en) * 2012-09-06 2015-02-19 Novartis Ag Combination vaccines with serogroup B meningococcus and D/T/P
KR20150060986A (ko) 2012-10-02 2015-06-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 비선형 사카라이드 컨주게이트
MX364644B (es) 2012-11-21 2019-05-03 Serum Inst India Ltd Produccion de altos rendimientos de polisacaridos bacteriales.
SI2935299T1 (sl) 2012-12-20 2019-12-31 Pfizer Inc. Postopek glikokonjugacije
ITMI20130142A1 (it) 2013-01-31 2014-08-01 Biosynth Srl Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
JP6747968B2 (ja) 2013-03-18 2020-08-26 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 治療方法
CA2910119A1 (en) 2013-05-20 2014-11-27 Shantha Biotechnics Private Limited Purification of polysaccharide protein conjugates
US9981030B2 (en) 2013-06-27 2018-05-29 Academia Sinica Glycan conjugates and use thereof
US9359400B2 (en) 2013-07-11 2016-06-07 Novartis Ag Site-specific chemoenzymatic protein modifications
CN105636608A (zh) 2013-10-11 2016-06-01 默沙东和惠康基金会合资的希勒曼实验室私人有限公司 免疫原性增强的多糖-蛋白质缀合物及其快速高产的制备方法
US10378017B2 (en) 2013-12-02 2019-08-13 Brandeis University High temperature selection of nucleotide-supported carbohydrate vaccines and resulting glycosylated oligonucleotides
WO2015121783A1 (en) 2014-02-14 2015-08-20 Pfizer Inc. Immunogenic glycoprotein conjugates
AU2015221820B2 (en) 2014-02-25 2019-01-31 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Novel synthetic oligomers of Neisseria meningitis serogroup X and process of preparing them
MY186874A (en) 2014-02-25 2021-08-26 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd A novel downstream process for purifying polysaccharides
EP3131576B1 (en) 2014-04-17 2021-06-30 Medizinische Hochschule Hannover Means and methods for producing neisseria meningitidis capsular polysaccharides of low dispersity
CN104069504B (zh) 2014-05-11 2019-09-24 江苏康泰生物医学技术有限公司 一种增强多糖蛋白结合物免疫原性的方法
WO2015179270A2 (en) 2014-05-19 2015-11-26 Board Of Regents, The University Of Texas System Combinatorial platform for the display of surface adjuvants and antigens
EP3148577B1 (en) 2014-05-24 2021-01-20 Biological E Limited Novel semi-synthetic meningococcal conjugate vaccine
CU20170046A7 (es) * 2014-10-09 2017-06-05 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd Proceso mejorado para la conjugación y conjugados sintéticos de oligosacarido-proteina novedosos obtenidos del mismo
CN107249626A (zh) 2015-02-19 2017-10-13 辉瑞大药厂 脑膜炎奈瑟球菌组合物及其方法
EP3288983B1 (en) 2015-04-28 2025-10-29 Biological E Limited Method for separation of protein and other impurities from microbial capsular polysaccharides
CN104998255B (zh) 2015-06-30 2018-08-28 北京祥瑞生物制品有限公司 新型acyw135群脑膜炎球菌结合疫苗及其制备方法
WO2017006349A1 (en) 2015-07-04 2017-01-12 Bharat Biotech International Limited Polysaccharide vaccine formulations and processes for industrial production of bacterial polysaccharides
CN105061629A (zh) 2015-08-31 2015-11-18 成都欧林生物科技股份有限公司 A群脑膜炎球菌荚膜粗多糖纯化工艺
RU2021135165A (ru) 2015-11-17 2021-12-29 Пфайзер Инк. Среды и способы ферментации для производства полисахаридов в бактериальной клеточной культуре
BR112018068523A2 (pt) 2016-03-15 2019-01-22 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd novos conjugados de polissacarídeo-proteína e processo para obter os mesmos
WO2018045286A1 (en) 2016-09-02 2018-03-08 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
US20200061542A1 (en) 2017-02-24 2020-02-27 Merck Sharp & Dohme Corp. Methods for improving filterability of polysaccharide-protein conjugate reactions

Also Published As

Publication number Publication date
CN109890413B (zh) 2024-04-16
ES2974992T3 (es) 2024-07-02
US20190175718A1 (en) 2019-06-13
AU2024223993A1 (en) 2024-10-24
DK3506935T3 (en) 2024-04-02
AU2017321863A1 (en) 2019-04-11
EP3506935A1 (en) 2019-07-10
RS65362B1 (sr) 2024-04-30
CN118236477B (zh) 2025-04-25
EP4309670A3 (en) 2024-07-17
JP2022065099A (ja) 2022-04-26
SA519401227B1 (ar) 2022-02-28
JP7028932B2 (ja) 2022-03-02
BR112019003992A2 (pt) 2019-05-28
CA3033364A1 (en) 2018-03-08
WO2018045286A1 (en) 2018-03-08
US11147866B2 (en) 2021-10-19
US11707514B2 (en) 2023-07-25
EP3506935B1 (en) 2024-01-10
CN118236477A (zh) 2024-06-25
PH12019500399B1 (en) 2024-05-15
JP2019526573A (ja) 2019-09-19
KR20190044663A (ko) 2019-04-30
FI3506935T3 (fi) 2024-04-17
SG11201901394XA (en) 2019-03-28
PH12019500399A1 (en) 2019-05-20
PT3506935T (pt) 2024-04-01
MX2019002489A (es) 2019-10-21
KR102692762B1 (ko) 2024-08-08
JP7329087B2 (ja) 2023-08-17
KR20230135178A (ko) 2023-09-22
ZA201901402B (en) 2024-06-26
HUE066007T2 (hu) 2024-07-28
EP4309670A2 (en) 2024-01-24
HRP20240433T1 (hr) 2024-07-05
PL3506935T3 (pl) 2024-06-10
SI3506935T1 (sl) 2024-06-28
LT3506935T (lt) 2024-04-25
CN109890413A (zh) 2019-06-14
US20230310567A1 (en) 2023-10-05
AU2017321863B2 (en) 2024-07-11
US20250152693A1 (en) 2025-05-15
US20210401964A1 (en) 2021-12-30
JP2021001182A (ja) 2021-01-07

Similar Documents

Publication Publication Date Title
JP7028932B2 (ja) ナイセリア・メニンギティディスのワクチン
AU2018225099B2 (en) Enhancing immunogenicity of Streptococcus pneumoniae polysaccharide-protein conjugates
AU2016295566B2 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP3576759B1 (en) Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
KR102486891B1 (ko) 다가 폐렴구균성 다당류-단백질 접합체 조성물
JP6808658B2 (ja) 多価肺炎球菌コンジュゲートワクチン
JP2020533437A (ja) 肺炎球菌多糖体および免疫原性多糖体−キャリアタンパク質コンジュゲートでのその使用
JP2025084846A (ja) 免疫原性血清型３５ｂ肺炎球菌多糖類－タンパク質コンジュゲート及びそれを作成するためのコンジュゲーションプロセス
KR102906912B1 (ko) 네이세리아 메닌기티디스 백신
HK40005680B (en) Neisseria meningitidis vaccine
HK40005680A (en) Neisseria meningitidis vaccine
EA040960B1 (ru) Вакцина против neisseria meningitidis
US20220031829A1 (en) Combined immunization against meningococcal disease and human papillomavirus
HK1195512A1 (zh) 多糖-蛋白轭合物疫苗

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200331

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200331

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200331

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20200420

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200701

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200721

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200728

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200811

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200910

R150 Certificate of patent or registration of utility model

Ref document number: 6764021

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250